Does Rallies show live market data for SNDX?

Rallies combines live market context with ticker research for SNDX, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.

SNDX (Syndax Pharmaceuticals, Inc.) Stock Analysis

Syndax Pharmaceuticals, Inc. (SNDX) is a publicly traded Healthcare sector company. As of May 21, 2026, SNDX trades at $20.13 with a market cap of $1.72B and a P/E ratio of -6.10. SNDX moved +4.08% today. Year to date, SNDX is -0.45%; over the trailing twelve months it is +90.44%. Its 52-week range spans $8.58 to $25.59. Analyst consensus is strong buy with an average price target of $39.91. Rallies surfaces SNDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the latest SNDX stock research?

Syndax Pharmaceuticals, Inc. (SNDX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. SNDX moved +4.08% today. Analyst consensus is strong buy.

SNDX Key Metrics

Key financial metrics for SNDX
Metric	Value
Price	$20.13
Market Cap	$1.72B
P/E Ratio	-6.10
EPS	$-3.29
Dividend Yield	0.00%
52-Week High	$25.59
52-Week Low	$8.58
Volume	0
Avg Volume	0
Revenue (TTM)	$172.35M
Net Income	$-285.42M
Gross Margin	0.00%

Latest SNDX News

Syndax Highlights 12 Revuforj Abstracts Accepted for EHA 2026 — May 12, 2026
Syndax Q1 Revenue $64.9M, 50% Transplant Rate Delays Maintenance Restarts — May 1, 2026
Syndax Q1 Revenue Soars 224% to $64.9M, Revuforj Hits $48.9M — Apr 30, 2026
Syndax’s Revuforj Q4 Revenue Jumps 38% to $44.2M, 1,050 Patients Treated — Feb 27, 2026
Syndax Posts $68.7M Q4, $172.4M FY25 Revenue; Revuforj Up 38%, Niktimvo Up 22% — Feb 26, 2026

Recent SNDX Insider Trades

Metzger Michael A sold 17.16K (~$360.82K) on Feb 9, 2026.
Goldan Keith A. sold 3.41K (~$71.71K) on Feb 9, 2026.
Metzger Michael A sold 7.41K (~$152.84K) on Feb 6, 2026.

SNDX Analyst Consensus

12 analysts cover SNDX: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $39.91.

Common questions about SNDX

What can I research for SNDX on Rallies?: Syndax Pharmaceuticals, Inc. (SNDX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. SNDX moved +4.08% today. Analyst consensus is strong buy.
Does Rallies show live market data for SNDX?: Rallies combines live market context with ticker research for SNDX, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.